Evidence map›Paper›PMID 36578077›Full record

ArticleMicrobial cell factories2022

High-efficiency production of 5-hydroxyectoine using metabolically engineered Corynebacterium glutamicum.

Lukas Jungmann, Sarah Lisa Hoffmann, Caroline Lang, Raphaela De Agazio, Judith Becker, Michael Kohlstedt, Christoph Wittmann

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Metabolic Profile of the Genome-ReducedACS synthetic biology · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lukas JungmannInstitute of Systems Biotechnology, Saarland University, Campus A1.5, Saarbrücken, Germany.
Sarah Lisa HoffmannInstitute of Systems Biotechnology, Saarland University, Campus A1.5, Saarbrücken, Germany.
Caroline LangInstitute of Systems Biotechnology, Saarland University, Campus A1.5, Saarbrücken, Germany.
Raphaela De AgazioInstitute of Systems Biotechnology, Saarland University, Campus A1.5, Saarbrücken, Germany.
Judith BeckerInstitute of Systems Biotechnology, Saarland University, Campus A1.5, Saarbrücken, Germany.
Michael KohlstedtInstitute of Systems Biotechnology, Saarland University, Campus A1.5, Saarbrücken, Germany.
Christoph WittmannInstitute of Systems Biotechnology, Saarland University, Campus A1.5, Saarbrücken, Germany. christoph.wittmann@uni-saarland.de.
Saarland University · DE

Funding

Bundesministerium für Bildung und Forschung EXTRA (031B0822A)
6 · The paper itself

Abstract

backgroundExtremolytes enable microbes to withstand even the most extreme conditions in nature. Due to their unique protective properties, the small organic molecules, more and more, become high-value active ingredients for the cosmetics and the pharmaceutical industries. While ectoine, the industrial extremolyte flagship, has been successfully commercialized before, an economically viable route to its highly interesting derivative 5-hydroxyectoine (hydroxyectoine) is not existing.

resultsHere, we demonstrate high-level hydroxyectoine production, using metabolically engineered strains of C. glutamicum that express a codon-optimized, heterologous ectD gene, encoding for ectoine hydroxylase, to convert supplemented ectoine in the presence of sucrose as growth substrate into the desired derivative. Fourteen out of sixteen codon-optimized ectD variants from phylogenetically diverse bacterial and archaeal donors enabled hydroxyectoine production, showing the strategy to work almost regardless of the origin of the gene. The genes from Pseudomonas stutzeri (PST) and Mycobacterium smegmatis (MSM) worked best and enabled hydroxyectoine production up to 97% yield. Metabolic analyses revealed high enrichment of the ectoines inside the cells, which, inter alia, reduced the synthesis of other compatible solutes, including proline and trehalose. After further optimization, C. glutamicum Ptuf ectD

conclusionsC. glutamicum is a well-known and industrially proven host, allowing the synthesis of commercial products with granted GRAS status, a great benefit for a safe production of hydroxyectoine as active ingredient for cosmetic and pharmaceutical applications. Because ectoine is already available at commercial scale, its use as precursor appears straightforward. In the future, two-step processes might provide hydroxyectoine de novo from sugar.

Indexed as

Amino Acids, DiaminoCorynebacterium glutamicumBacteriaAmino Acids, Diaminohydroxyectoine5-HydroxyectoineBiotransformationCorynebacterium glutamicumEctoineEctoine hydroxylaseExtremolyteHigh-value productIntracellular metaboliteProlineTrehalose

Identifiers

PMID36578077
PMCPMC9798599
OpenAlexW4312226318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.